
At CFS 2026, Martin Gleave, CM, MD, FRCSC, FACS, explained why higher-volume, high-grade prostate cancer is the sweet spot for perioperative ARPI therapy.
This video highlights a clinical-genomic risk classification system that is highly prognostic for distant metastasis and more accurate than clinical risk assessments.
In this video, Daniel Eidelberg Spratt, MD, of the University of Michigan, discusses how the use of a readily available genomic classifier combined with clinicopathologic variables can generate a simple to use clinical-genomic risk classification system that is highly prognostic for distant metastasis and more accurate than clinical risk assessments.
Spratt presented results of the study (






